Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xenogenics acquires Ideal BioStent assets
Xenogenics has also entered into a worldwide exclusive license with Rutgers University for rights to certain intellectual property related to the Ideal BioStent. The Ideal BioStent offers a
Xenogenics has also entered into a worldwide exclusive license with Rutgers University for rights to certain intellectual property related to the Ideal BioStent. The Ideal BioStent offers a
The patents cover oral formulations of leading injectables, like bevacizumab (Avastin), trastuzumab (Herceptin), adalimumab (Humira, etanercept (Enbrel), insulin glargine (Lantus), and many others. In addition, Access rebranded its
Based on an exclusive license and distribution agreement mutually signed in March of this year between Biofrontera and Itrom Trading Drug Store in Dubai, half of the initial
ORBIT-2 trial, a randomised, double-blind, placebo-controlled ORBIT-2 trial was conducted in Australia and New Zealand. The primary endpoint was the mean change in Pseudomonas aeruginosa density in sputum
The Phase I study was commenced during the first quarter of 2010 to evaluate the safety, tolerability and pharmacokinetic profile of QPI-1007 in patients with chronic nerve atrophy
Agensys and Seattle Genetics said that the study is designed to recruit up to 60 patients at multiple centers in the US. ASG-5ME is an antibody-drug conjugate (ADC)
Under the contract, Pfizer will make an upfront payment of $240m and Teuto will be eligible to receive a performance-based milestone payment. Pfizer has an option to acquire
The Classic I study was a randomised, double-blind, placebo-controlled clinical trial that compared Clolar in combination with cytarabine to cytarabine plus placebo in patients 55 years and older
Novartis posted a net income of $2.31bn for the third quarter 2010, compared to $2.11bn for the comparable period in 2009. The operating loss was $2.59bn, compared to
The software integration supports academic and commercial researchers studying genes affects and individuals response to drug treatments. According to the companies, joint customers will have a clear workflow